Macrocure names Nissim Mashiach CEO
This article was originally published in Clinica
Macrocure, a biotech specialising in cell therapy for hard-to-heal wounds, has appointed Nissim Mashiach president and CEO. Mr Mashiach most recently served as general manager at Ethicon, a Johnson & Johnson company. Prior to that, he was president and COO at Omrix Biopharmaceuticals, a company acquired by J&J for $438m in 2008 (www.clinica.co.uk, 22 December 2008).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.